A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2 by Kim, KS, Ejima, K, Iwanami, S, Fujita, Y, Ohashi, H, Koizumi, Y, Asai, Y, Nakaoka, S, Watashi, K, Aihara, K, Thompson, RN, Ke, R, Perelson, AS, Iwami, S

Modelling the effectiveness of an isolation strategy for managing mpox outbreaks with variable infectiousness profiles by Jeong, YD, Hart, W, Thompson, R, Ishikane, M, Nishiyama, T, Park, H, Iwamoto, N, Sakurai, A, Suzuki, M, Aihara, K, Watashi, K, Op de Coul, E, Ohmagari, N, Wallinga, J, Iwami, S, Miura, F

Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: a modeling study by Iwanami, S, Ejima, K, Kim, KS, Noshita, K, Fujita, Y, Miyazaki, T, Kohno, S, Miyazaki, Y, Morimoto, S, Nakaoka, S, Koizumi, Y, Asai, Y, Aihara, K, Watashi, K, Thompson, RN, Shibuya, K, Fujiu, K, Perelson, AS, Iwami, S, Wakita, T

An ACAT inhibitor suppresses SARS-CoV-2 replication and boosts antiviral T cell activity by Wing, PAC, Schmidt, NM, Peters, R, Erdmann, M, Brown, R, Wang, H, Swadling, L, Newman, J, Thakur, N, Shionoya, K, Morgan, SB, Hinks, TSC, Watashi, K, Bailey, D, Hansen, SB, Davidson, AD, Maini, MK, McKeating, JA

Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers by Kim, KS, Iwamoto, M, Kitagawa, K, Park, H, Hayashi, S, Tsukuda, S, Matsui, T, Atsukawa, M, Matsuura, K, Chuaypen, N, Tangkijvanich, P, Allweiss, L, Nishiyama, T, Nakamura, N, Fujita, Y, Kawakami, E, Nakaoka, S, Muramatsu, M, Aihara, K, Wakita, T, Perelson, AS, Dandri, M, Watashi, K, Iwami, S

Circadian control of hepatitis B virus replication by Zhuang, X, Forde, D, Tsukuda, S, D'arienzo, V, Mailly, L, Harris, JM, Wing, PAC, Borrmann, H, Schilling, M, Magri, A, Orbegozo Rubio, C, Maidstone, RJ, Iqbal, M, Garzon, M, Minisini, R, Pirisi, M, Butterworth, S, Balfe, P, Ray, DW, Watashi, K, Baumert, TF, McKeating, J

Hypoxic and pharmacological activation of HIFs inhibits SARS-CoV-2 infection of lung epithelial cells by Wing, P, Keeley, TP, Zhuang, X, Lee, JY, Prange-Barczynska, M, Tsukuda, S, Morgan, SB, Harding, AC, Argles, ILA, Kurlekar, S, Noerenberg, M, Thompson, CP, Huang, K-YA, Balfe, P, Watashi, K, Castello, A, Hinks, TSC, James, W, Ratcliffe, PJ, Davis, I, Hodson, EJ, Bishop, T, McKeating, J

Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment by Ohashi, H, Watashi, K, Saso, W, Shionoya, K, Iwanami, S, Hirokawa, T, Shirai, T, Kanaya, S, Ito, Y, Kim, KS, Nomura, T, Suzuki, T, Nishioka, K, Ando, S, Ejima, K, Koizumi, Y, Tanaka, T, Aoki, S, Kuramochi, K, Suzuki, T, Hashiguchi, T, Maenaka, K, Matano, T, Muramatsu, M, Saijo, M, Aihara, K, Iwami, S, Takeda, M, McKeating, JA, Wakita, T

The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells by Zhuang, X, Tsukuda, S, Wrensch, F, Wing, PAC, Schilling, M, Harris, JM, Borrmann, H, Morgan, SB, Cane, JL, Mailly, L, Thakur, N, Conceicao, C, Sanghani, H, Heydmann, L, Bach, C, Ashton, A, Walsh, S, Tan, TK, Schimanski, L, Huang, K-YA, Schuster, C, Watashi, K, Hinks, TSC, Jagannath, A, Vausdevan, SR, Bailey, D, Baumert, TF, McKeating, JA

A multicenter randomized controlled trial to evaluate the efficacy and safety of nelfinavir in patients with mild COVID-19 by Miyazaki, T, Hosogaya, N, Fukushige, Y, Takemori, S, Morimoto, S, Yamamoto, H, Hori, M, Ozawa, Y, Shiko, Y, Inaba, Y, Kurokawa, T, Hanaoka, H, Iwanami, S, Kim, K, Iwami, S, Watashi, K, Miyazawa, K, Umeyama, T, Yamagoe, S, Miyazaki, Y, Wakita, T, Sumiyoshi, M, Hirayama, T, Izumikawa, K, Yanagihara, K, Mukae, H, Kawasuji, H, Yamamoto, Y, Tarumoto, N, Ishii, H, Ohno, H, Yatera, K, Kakeya, H, Kichikawa, Y, Kato, Y, Matsumoto, T, Saito, M, Yotsuyanagi, H, Kohno, S